SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales surged to Rs. 59482.20 millions, up 48.45% for the March 2023 quarter as against Rs. 40068.80 millions during the corresponding quarter previous year.The Net Loss for the quarter ended March 2023 is Rs. -10208.20 millions as compared to Net Loss of Rs. -12862.10 millions of corresponding quarter ended March 2022OP of the company witnessed a marginal growth to 24809.50 millions from 13002.50 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 59482.20 40068.80 48.45 208121.40 155859.80 33.53 208121.40 155859.80 33.53
Other Income 1203.00 4404.90 -72.69 3292.90 11968.80 -72.49 3292.90 11968.80 -72.49
PBIDT 24809.50 13002.50 90.81 67518.90 38654.40 74.67 67518.90 38654.40 74.67
Interest 1614.50 911.90 77.05 4721.80 3881.00 21.66 4721.80 3881.00 21.66
PBDT -6182.90 -4459.00 38.66 33419.20 16568.10 101.71 33419.20 16568.10 101.71
Depreciation 4119.80 3541.40 16.33 16008.70 13499.50 18.59 16008.70 13499.50 18.59
PBT -10302.70 -8000.40 28.78 17410.50 3068.60 467.38 17410.50 3068.60 467.38
TAX -94.50 4861.70 -101.94 503.30 4068.50 -87.63 503.30 4068.50 -87.63
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -10208.20 -12862.10 -20.63 16907.20 -999.90 -1790.89 16907.20 -999.90 -1790.89
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 41.71 32.45 28.53 32.44 24.80 30.81 32.44 24.80 30.81

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×